Additionally, after 42 days of MZXD treatment, levels of complement factors C3, C4, and immunoglobulins IgG, IgM, and IgA in the plasma of patients with phlegm-dampness type Stage I hypertension were significantly reduced (p < 0.05). The gene discussed is CD40LG; the disease is Hypertension.